Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Medical And Pharmaceutical Industry Technology And Development Center maintains a highly focused patent prosecution profile within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action at the USPTO. This single matter is assigned to 1 distinct examiner, ensuring that the company's current legal efforts are concentrated on a specific set of claims under review by a single individual.
The pending action is located within 1 distinct art unit, which defines the technical peer group and examination standards applied to the application. JACKSON III, WALTER is the busiest examiner for the portfolio, currently managing the 1 pending office action. For the practitioner, this means that the entirety of the company's active prosecution rests with JACKSON III, WALTER, making this examiner the sole point of contact for current negotiations.
The alignment of the pending workload across a single art unit and examiner reflects a streamlined and highly focused prosecution state. There are no other pending matters to balance, allowing for a dedicated strategy centered on the current application. This administrative simplicity is characteristic of portfolios with limited active filings at the office, where JACKSON III, WALTER oversees the only active case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19107452 | USE OF COMPOSITION INCLUDING MESENCHYMAL STEM CELLS FOR ALLEVIATING MYELOFIBROSIS | JACKSON III, WALTER | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19107452 | USE OF COMPOSITION INCLUDING MESENCHYMAL STEM CELLS FOR ALLEVIATING MYELOFIBROSIS | JACKSON III, WALTER | 1638 | §102§103 | Non-Final OA | — | Pending | Feb 27, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedical And Pharmaceutical Industry Technology And Development Center has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Walter Jackson III has the most, with 1 of Medical And Pharmaceutical Industry Technology And Development Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
